Kumar Prabhash
Leads medical oncology at Tata Memorial and its programme of pragmatic trials that make treatments affordable.
Kumar Prabhash has led trials of oral metronomic chemotherapy in head and neck cancer, low-cost EGFR-TKI strategies in lung cancer, and the department's low-dose immunotherapy studies.
| Title | Journal | Year |
|---|---|---|
| Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer | Journal of Clinical Oncology | 2020 |
Pages like this
not linked directly; found by shared links- PersonVijay Patil
Shares Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Head and neck squamous cell carcinoma.
- PersonVanita Noronha
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- PersonRajendra Badwe
Shares Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre.
- IdeaCommunity health workers with smartphone AI screen for mouth cancer in South Asia
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.
- PersonShun Lu
Shares MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer, EGFR, Non-small-cell lung cancer.
- PersonPankaj Chaturvedi
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.
- PersonJohn V. Heymach
Shares EGFR, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- IdeaValidate low-cost metronomic oral regimens in phase 3 and carry them into guidelines
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.